Fara Berkowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development — Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas — — Fast tracks establishment of Sanofi’s recently announced  mRNA Center of Excellence — — Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology — PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — As part of Sanofi’s endeavor to accelerate the application of messenger RNA ...

Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI Viviane Monges joins Sanofi as Chair of the Supervisory Board of EUROAPI Roy Papatheodorou appointed EVP, General Counsel and Head of Legal, Ethics & Business Integrity Brendan O'Callaghan appointed EVP, Global Head of Industrial Affairs P ly 29, 2021 - Karen Linehan and Philippe Luscan, who have led Legal, Ethics & Business Integrity (LEBI) and Industrial Affairs at Sanofi for the last 14 and 13 years respectively have decided to retire. Karen will retire on December 31, 2021 and Philippe later in 2022....

MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers July 10, 2021 Results from a head-to-head Phase 3 study, evaluating the immune response of MenQuadfi® to serogroup C, one of the main se...

Sanofi: Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis in adults with moderate-to-severe atopic dermatitis Dupixent is the first and only available systemic treatment for atopic dermatitis that has been studied in adults for up to 3 years in a Phase 3 trial PARIS and TARRYTOWN, N.Y. - June 28 , 2021- Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following ...

Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with =50% PD-L1 expression Approval